Anonymoose wrote:I wasn't speaking of the Blaney study. I was referring to the ideas of the authors of the page.
It follows that any substance that slows the innate immune response will decrease this battle between man and microbe, causing the patient to feel better. The more the immune response is slowed, the greater the decrease in inflammation and inflammatory markers. But while such measures can make the patient appear as if they are getting better for years, ultimately the bacteria causing their disease are able to spread much more easily and exacerbate the disease state over the long-term.
Our molecular and clinical data shows that 25-D, like the pathogens we describe above, binds the Vitamin D Receptor and slows its activity.[1] Since the VDR largely controls the innate immune response, increasing 25-D levels could easily display the pattern of immunosuppression described above. This begs the question – is 25-D a miracle curative substance or simply an excellent palliative?
We have found that when 1,25-D is high, the vitamin D feedback pathways naturally downregulate levels of 25-D. This means that what is now viewed as “deficiency” could simply be a result of the chronic disease process. Under such circumstances, allowing people to create extra 25-D by raising the DRI is not only useless but harmful.
Right. Blaney was a joint study with Amy Proal, but your reference is to the Marshall hypothesis that it is all bacterial, we just can't see the bacteria and vitamin D supplementation is harmful in the long run.
The logic and data behind this leave me baffled. Proal et alia are in a minority in arguing that 25(OH)D3 binds to the VDR and is therefore immunosuppressive.
It is the logical of this that I have trouble understanding (it may be right, I just don't understand it). It appears to assume that the innate immune system is only pro-inflammatory when it is both pro- and anti-inflammatory. Further, calcitriol both activates and deactivates immune cells.
Emerging molecular evidence suggests that symptomatic improvements among those administered vitamin D is the result of 25-D's ability to temper bacterial-induced inflammation by slowing VDR activity. While this results in short-term palliation, persistent pathogens that may influence disease progression, proliferate over the long-term.
This inflammatory response is being induced by the cells attacked by the bacteria. For that to happen, calcitriol has to be able to act through VDRs to initiate the pro-inflammatory response. That tells me the VDRs are actually working or there would be no inflammatory response.
The only way to temper that response is by calcitriol acting through the VDR to set off programmed cell death in the inflammatory immune cells.
in other words, it is working or it isn't, but saying that it dampens an immune response by blocking the very gateway to dampening an immune response seems to me to stand logic on its head.
Maybe i'm missing something. I certainly don't think I'm as smart as the authors or as knowledgeable in this area.
I think the problem with all this is that no one can go in with a movie camera and see what happens step by step especially down to the level of the VDRs. Everyone is forced to guess what is happening based on the state of things that can be observed.
Prior to Hayes, there was an assumption by some that the VDRs were blocked in MS by EBV (and by extension something in the disease itself was blocking the VDRs in EAE). But if that were true, you wouldn't see the response in the death of pro-inflammatory immune cells that Hayes has measured, along with the proliferation of anti-inflammatory cells when the mice are given a dose of calcitriol. It can only work through the VDRs so they have to be functional for these changes to happen.
At least in EAE, those pro-inflammatory cells do not undergo programmed cell death regardless of the level of 25(OH)D3, nor do high levels make the disease worse.
Some day, Marshall et alia may be able to prove the existence of the stealth bacteria, but they haven't convinced me with their arguments so far.